Cross-ancestry proteome-wide mendelian randomization of plasma proteins and breast cancer susceptibility.
Researchers identified protein targets for breast cancer prevention by combining genetic data across multiple ancestry groups, prioritizing novel candidates for future drug development.
Cross-ancestry proteome-wide MR using cis-pQTLs for 1,962 plasma proteins from 34,557 UK Biobank participants identified 12 candidate causal proteins for breast cancer, with LRRC25, PARK7, and LRRC37A2 achieving the most robust evidence. The cross-ancestry design and integration with All of Us replication dataset represent a methodological advance over prior single-ancestry proteomics studies, prioritizing novel druggable targets for breast cancer prevention.
What the study was
- Study design
- Cross-ancestry proteome-wide Mendelian randomization study
- Category
- Precision oncology and genomic medicine
- Maturity
- Exploratory
- Journal
- J Natl Cancer Inst
Why it surfaced
Published in JNCI; National Cancer Institute authorship; cross-ancestry MR with large-scale proteomics is a methodological frontier in precision oncology; 4 newly prioritized proteins may represent future therapeutic or biomarker targets. Limitation: MR is causal inference, not prospective intervention evidence.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.